2416-P: Immune Checkpoint Inhibitor Pembrolizumab–Induced Autoimmune Diabetes Mellitus Presenting as Recurrent Diabetic Ketoacidosis
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2416-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SHRIYA SHARMA und 3 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Immune checkpoint inhibitors (ICIs), including pembrolizumab, have transformed cancer therapy but are associated with immune-related adverse events, including endocrinopathies. Immune checkpoint inhibitor-induced diabetes mellitus is a rare but potentially life-threatening complication characterized by abrupt insulin deficiency and frequent presentation with diabetic ketoacidosis. We report a case of pembrolizumab-associated autoimmune diabetes presenting with recurrent diabetic ketoacidosis to highlight the importance of early recognition.
Methods
Clinical data were obtained through retrospective review of the patient’s electronic medical record.
Results
A 79 year old male with metastatic melanoma on pembrolizumab presented with recurrent diabetic ketoacidosis despite recent initiation of basal-bolus insulin therapy. Laboratory evaluation revealed severe hyperglycemia, high anion gap metabolic acidosis, elevated lactate, and acute kidney injury. HgbA1c obtained during a hospitalization four days earlier was 9.3%.The patient had previously been on Metformin for Type 2 diabetes for several years. Given the abrupt onset of insulin dependence, autoimmune diabetes was suspected. Testing demonstrated undetectable C-peptide and markedly elevated GAD-65 antibodies, with negative IA-2 antibodies, normal insulin level, and low proinsulin, consistent with immune-mediated B cell destruction. The patient was diagnosed with immune checkpoint inhibitor-induced autoimmune diabetes and transitioned to a revised basal-bolus insulin regimen prior to discharge.
Conclusion
Immune checkpoint inhibitor-induced autoimmune diabetes can present abruptly with severe insulin deficiency and recurrent diabetic ketoacidosis. Early recognition is critical, as B-cell failure is often rapid and irreversible. Routine glucose monitoring and heightened clinical awareness in patients receiving immune checkpoint inhibitors may prevent severe metabolic complications. Disclosure S. Sharma: None. M. Ramakrishna Reddy: None. R. Gopavaram: None. A. Mazhar: None.
Zitieren
APA
SHARMA, S., REDDY, M. R., GOPAVARAM, R. R., & MAZHAR, A. (2026). 2416-P: Immune Checkpoint Inhibitor Pembrolizumab–Induced Autoimmune Diabetes Mellitus Presenting as Recurrent Diabetic Ketoacidosis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2416-p
Vancouver
SHARMA S, REDDY MR, GOPAVARAM RR, MAZHAR A. 2416-P: Immune Checkpoint Inhibitor Pembrolizumab–Induced Autoimmune Diabetes Mellitus Presenting as Recurrent Diabetic Ketoacidosis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2416-p
BibTeX
@article{SHARMA2026,
author = {SHARMA, SHRIYA and REDDY, MURALI RAMAKRISHNA and GOPAVARAM, RAVIKISHORE REDDY and MAZHAR, AYMN},
title = {2416-P: Immune Checkpoint Inhibitor Pembrolizumab–Induced Autoimmune Diabetes Mellitus Presenting as Recurrent Diabetic Ketoacidosis},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2416-p}
}
EUVIMED